Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immediate radiotherapy best for prostate cancer:

This article was originally published in Clinica

Executive Summary

A US study has fuelled the debate over the best way to manage localised advanced prostate cancer after showing that men with the disease are more likely to survive if they undergo initial radiotherapy than opt for a watchful waiting policy. In an analysis of data from around 1,500 patients, a team, led by Dr Mack Roach of the University of California, San Francisco, found that the radiotherapy group had a greater chance of surviving 10 years compared with the watchful waiting group. The study appears in the March edition of The Journal of Urology.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT077617

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel